GlaxoSmithKline and Novartis sign $25 billion worth of drug deals
Thinkstock


Two of the world's biggest drugmakers, Britain's GlaxoSmithKline and Switzerland's Novartis, announced a complex hodgepodge of deals worth at least $25 billion on Tuesday. The main components:
* Novartis agreed to buy Glaxo's oncology business for between $14.5 billion and $16 billion* Glaxo is buying Novartis' vaccine business for between $5.3 billion and $7.1 billion* The two companies are combining their consumer health (over-the-counter) divisions, with Glaxo taking 63.5 percent of the joint venture* Eli Lilly will purchase Novartis' animal health unit for about $5.4 billion
The transactions will let Novartis focus on high-margin businesses like cancer drugs while Glaxo boosts its position in consumer goods and the low-margin, high-volume vaccine market. But the pharmaceutical giants aren't the only drugmakers making high-stakes deals. The Wall Street Journal says the $25 billion worth of transactions cap a 24-hour period where "deals worth, conservatively, $65 billion" were announced, not counting Pfizer's unsolicited $101 billion offer to buy Britain's AstraZeneca.
"The Novartis-Glaxo deal and rumors about a potential AstraZeneca acquisition by Pfizer are giving the pharma sector a decent run this morning," Danish strategist Witold Bahrke tells Bloomberg News. "It's also fueling further M&A expectations."
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Florida erases rainbow crosswalk at Pulse nightclub
Speed Read The colorful crosswalk was outside the former LGBTQ nightclub where 49 people were killed in a 2016 shooting
-
Trump says Smithsonian too focused on slavery's ills
Speed Read The president would prefer the museum to highlight 'success,' 'brightness' and 'the future'
-
Trump to host Kennedy Honors for Kiss, Stallone
Speed Read Actor Sylvester Stallone and the glam-rock band Kiss were among those named as this year's inductees
-
White House seeks to bend Smithsonian to Trump's view
Speed Read The Smithsonian Institution's 21 museums are under review to ensure their content aligns with the president's interpretation of American history
-
Charlamagne Tha God irks Trump with Epstein talk
Speed Read The radio host said the Jeffrey Epstein scandal could help 'traditional conservatives' take back the Republican Party
-
CBS cancels Colbert's 'Late Show'
Speed Read 'The Late Show with Stephen Colbert' is ending next year
-
Shakespeare not an absent spouse, study proposes
speed read A letter fragment suggests that the Shakespeares lived together all along, says scholar Matthew Steggle
-
New Mexico to investigate death of Gene Hackman, wife
speed read The Oscar-winning actor and his wife Betsy Arakawa were found dead in their home with no signs of foul play